Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00710034
Recruitment Status : Completed
First Posted : July 3, 2008
Results First Posted : December 6, 2017
Last Update Posted : December 6, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Tobacco Use Disorder
Interventions: Other: Oral tobacco
Drug: Nicotine Gum

  Participant Flow

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Nicotine Gum

Nicotine replacement therapy

Nicotine Gum: 4 mg Nicotine gum


Oral tobacco

Oral tobacco: Snus

Total Total of all reporting groups

Baseline Measures
   Nicotine Gum   Snus   Total 
Overall Participants Analyzed 
[Units: Participants]
 195   196   391 
[Units: Participants]
Count of Participants
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      195 100.0%      196 100.0%      391 100.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
[Units: Years]
Mean (Standard Deviation)
 43.9  (12.5)   43.2  (12.5)   43.9  (12.5) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      95  48.7%      89  45.4%      184  47.1% 
Male      100  51.3%      107  54.6%      207  52.9% 
Region of Enrollment 
[Units: Participants]
United States   195   196   391 

  Outcome Measures

1.  Primary:   Product Effect on Complete Substitution for Smoking   [ Time Frame: 6 week post smoking substitution ]

2.  Primary:   Number of Cigarettes Smoked   [ Time Frame: 6 weeks post cigarette substitution ]

3.  Primary:   Number of Products Used   [ Time Frame: 6 weeks post smoking substitution ]

4.  Secondary:   Products Effect on Withdrawal Symptoms.   [ Time Frame: Week 1-12 post switching ]

5.  Secondary:   Product Effect on Biomarkers of Exposure and Toxicity   [ Time Frame: Baseline and Week 4 post smoking substitution ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dorothy Hatsukami, Ph.D.
Organization: University of Minnesota
phone: 612-626-2121


Responsible Party: University of Minnesota - Clinical and Translational Science Institute Identifier: NCT00710034     History of Changes
Other Study ID Numbers: 1R01 CA135884-2
1R01CA135884 ( U.S. NIH Grant/Contract )
First Submitted: July 2, 2008
First Posted: July 3, 2008
Results First Submitted: November 30, 2016
Results First Posted: December 6, 2017
Last Update Posted: December 6, 2017